| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Rui-Min Lai, Shan Lin, Miao-Miao Wang, Na Li, Jia-Hui Zhou, Xiao-Yu Lin, Tian-Bin Chen, Yue-Yong Zhu and Qi Zheng |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Clinical Research Center for Liver and Intestinal Diseases of Fujian Province |
2021Y2006 |
| Natural Science Fundation of Fujian Province |
2021J01224 |
|
| Corresponding Author |
Qi Zheng, PhD, Chief Physician, Professor, Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fujian Clinical Research Center for Hepatopathy and Intestinal Diseases, No. 20 Chazhong Road, Taijiang District, Fuzhou 350005, Fujian Province, China. bei0825@163.com |
| Key Words |
Tenofovir alafenamide; Entecavir; Hepatitis B virus; Serum lipid; Metabolic factor |
| Core Tip |
This study compared the effects of tenofovir alafenamide (TAF) and entecavir on serum lipid levels in chronic hepatitis B patients. The results suggested that TAF-treated patients had significantly increased triglycerides, and total cholesterol levels compared to that at baseline, while there was no difference in the entecavir group. However, dyslipidemia caused by TAF therapy did not increase the incidence of nonalcoholic fatty liver disease. Our findings indicated that the potential impact of anti-viral therapy on the lipid profile may be an important consideration in the treatment choices for chronic hepatitis B patients with abnormal metabolic factors. |
| Publish Date |
2023-08-22 07:39 |
| Citation |
Lai RM, Lin S, Wang MM, Li N, Zhou JH, Lin XY, Chen TB, Zhu YY, Zheng Q. Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients. World J Hepatol 2023; 15(8): 964-972 |
| URL |
https://www.wjgnet.com/1948-5182/full/v15/i8/964.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v15.i8.964 |
